
ITI Pharma and Healthcare Fund (G)
Sectoral FundNAV
16.59(-0.94%)Fund Size (CR)
₹266.05Expense Ratio
2.62Scheme Type
Active FundValue Research
-
Min. investment
₹5,000Minimum Additional Investment
₹1,000Minimum SIP Investment
₹500Minimum Withdrawal
₹1,000Exit Load
0.5%Return Since Launch
10.75%
Basic Details
Scheme Manager
Animesh Singh
Bench Mark
NIFTY Healthcare TRI
Type
OPEN
Lumpsum Returns
| Period Invested For | ₹10,000 Invested on | Latest Value | Absolute Returns | Annualised Returns | Category Avg | Rank within Category |
|---|---|---|---|---|---|---|
| 1 Week | October 16, 2026 | 9739.69 | -2.60% | - | -3.50% | 67/256 |
| 1 Month | September 23, 2026 | 8994.17 | -10.06% | - | -6.72% | 211/256 |
| 3 Month | July 23, 2026 | 9499.87 | -5.00% | - | -3.93% | 113/252 |
| 6 Month | April 23, 2026 | 10552.63 | 5.53% | - | 1.04% | 101/252 |
| 1 Year | October 23, 2025 | 10011.10 | 0.11% | 0.11% | -2.53% | 71/224 |
| 3 Year | October 23, 2023 | 15458.54 | 54.59% | 15.61% | 12.64% | 52/162 |
| 5 Year | - | - | - | - | - | -/- |
| Since Inception | November 8, 2021 | 16590.10 | 65.90% | 10.75% | 10.39% | 144/256 |
Note: Lumpsum Returns since Inception Date.
SIP Returns
| Period Invested For | ₹10,000 Invested on | Investments | Latest Value | Absolute Returns | Annualised Returns |
|---|---|---|---|---|---|
| 1 Year | November 3, 2025 | 1,20,000 | 121882.24 | 1.57% | 1.57% |
| 3 Year | November 1, 2023 | 3,60,000 | 392455.10 | 9.02% | 2.92% |
| 5 Year | December 1, 2021 | 5,90,000 | 791473.66 | 34.15% | 6.05% |
| 10 Year | - | - | - | - | - |
Note: SIP Returns since Inception Date.
Tax Treatment
If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 10%, if your total long term capital gain exceeds 1 lakh. Any cess/surcharge is not included.If sold before 1 year from purchase date, short term capital gain tax will be applicable. Current tax rate is 15%. Any cess/surcharge is not included in the 15%.
Risk Ratios
4.83%
Standard Deviation
0.95%
Beta
0.71%
Sharpe Ratio
0.06%
Treynor's Ratio
-1.27%
Jension's Alpha
Asset Allocation
Sector Allocation
Top 10 stock holding in portfolio
| Stock Invested in | % of Total Holdings | Quantity | Value (Cr) | Asset Type | Segment |
|---|---|---|---|---|---|
| Sun Pharma.Inds. | 11.96% | 175147 | 31.82 | Equity | Pharmaceuticals |
| Divi's Lab. | 9.51% | 27227 | 25.30 | Equity | Pharmaceuticals |
| Apollo Hospitals | 5.45% | 17745 | 14.49 | Equity | Healthcare |
| Dr Reddy's Labs | 4.78% | 103145 | 12.72 | Equity | Pharmaceuticals |
| Torrent Pharma. | 4.78% | 26473 | 12.71 | Equity | Pharmaceuticals |
| Max Healthcare | 4.49% | 128340 | 11.93 | Equity | Healthcare |
| Cipla | 4.19% | 82778 | 11.14 | Equity | Pharmaceuticals |
| Laurus Labs | 4.02% | 54023 | 10.70 | Equity | Pharmaceuticals |
| Aurobindo Pharma | 4.01% | 63858 | 10.68 | Equity | Pharmaceuticals |
| Mankind Pharma | 3.78% | 40139 | 10.05 | Equity | Pharmaceuticals |
Peer Comparison
| Scheme Name | Value Research | Asset Size (Cr) | 1M | 3M | 6M | 1Y | 3Y |
|---|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Direct (G) | 3501.37 | -9.69% | -3.02% | 11.12% | 15.90% | 27.94% | |
| HDFC Pharma and Healthcare Fund - Direct (IDCW) | 3501.37 | -9.69% | -3.02% | 11.12% | 15.90% | 27.94% | |
| Kotak Healthcare Fund - Direct (IDCW) | 825.14 | -10.43% | -2.96% | 13.41% | 14.68% | - | |
| Kotak Healthcare Fund - Direct (G) | 825.14 | -10.43% | -2.96% | 13.41% | 14.68% | - | |
| SBI Automotive Opportunities Fund - Direct (IDCW) | 6070.82 | -8.89% | -1.67% | 7.82% | 12.17% | - |
List of Schemes under ITI Mutual Fund
News
ITI Mutual Fund announces Ceasation of Key Personnel
ITI Mutual Fund announces that Mr. Vikas Pandya shall cease to be the Head ' Compliance, Legal & Secretarial and Compliance Officer of ITI AMC with effect from the close of business hours on July 27, 2026.Powered by Capital Market - Live News
ITI Mutual Fund announces Appointment of Key Personnel
ITI Mutual Fund has announced that Mr. Dhruvkumar Trivedi has been appointed as an Acting Compliance Officer and Company Secretary for Mutual Fund business and is a Key Personnel at ITI Asset Management Ltd, with effect from July 27, 2026.Name: Mr. Dhruvkumar Trivedi,
Age: 33 years
Designation: Acting Compliance Officer and Company Secretary
Qualification: ACS, LLB
Powered by Capital Market - Live News
Fund House Details & Investment Objective
Date of Incorporation
October 18, 2021
Total AUM (Cr)
₹266.05
ITI Pharma and Healthcare Fund (G) is an Sectoral Fund-oriented fund from the renowned AMC, ITI Mutual Fund. Launched in October 18, 2021, this fund is managed by Animesh Singh. With assets under management (AUM) worth ₹266.05 (Cr), as of October 23, 2026, ITI Pharma and Healthcare Fund (G) is categorized as a Sectoral Fund within its segment. The fund has generated a return of 10.75% since its launch.
The current NAV of ITI Pharma and Healthcare Fund (G) is ₹16.59, as on October 23, 2026. The fund's benchmark index is NIFTY Healthcare TRI. You can invest in ITI Pharma and Healthcare Fund (G) via both lumpsum and SIP modes. The minimum SIP amount in the fund is ₹500 while the minimum lumpsum investment is ₹5,000.
Being an open-ended fund, you can exit the fund anytime subject to applicable exit loads:
The fund has generated 15.61% and undefined% CAGR in the last 3 and 5 years respectively.
The fund aims to provide long-term capital appreciation and growth, by investing in a mix of financial instruments 99.31% in Equity, 0.69% in cash and cash equivalents.
The top 5 sectors the fund invests in are: 74.79% in Pharmaceuticals & Biotech, 20.90% in Healthcare Services, 1.48% in Healthcare Equipment & Su, 1.22% in Consumer Durables, 0.92% in Chemicals & Petrochemical
Mutual Fund Categories
Types of Mutual Funds
Debt Funds
Access debt markets and enjoy interest income from bonds and debentures. Ideal for conservative short-term investors
Hybrid Funds
Enjoy best of both the worlds - equity and debt. Ideal for beginners with medium-term investment horizon
Equity Funds
Invest in large, mid, and small cap sector stocks to enjoy capital appreciation. Ideal for aggressive, long-term investors